ViiV Healthcare announces positive CHMP opinion for Rukobia (fostemsavir), a first-in-class attachment inhibitor for the treatment of adults with multidrug-resistant HIV with few treatment options available

Fostemsavir addresses a critical unmet need in HIV care for those with little to no treatment options left.